The Rise of Antifungal-Resistant Dermatophyte Infections: What Dermatologists Need to Know.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Rapid PCR-based diagnosis of superficial mycoses with ROC-optimized cutoffs.Microbiology spectrum · 2026
   Article
2. Recognizing a potential new endemic threat as emerging Trichophyton mentagrophytes genotype VII dermatophyte becomes a sexually transmitted pathogen: clinical evidence, transmission drivers, and the risk of establishing a new endemic threat.Infection · 2026
   Review
3. Fungicidal Activity of the Nitroimidazole-Thiosemicarbazide Derivative 1-[(1-methyl-4-nitroimidazol-2-yl)carbonyl]-4-(3-methylophenyl)thiosemicarbazide AgainstPathogens (Basel, Switzerland) · 2026
   Article
4. Resistance and Recalcitrance in Dermatophytosis: Mechanistic and Clinical Considerations for Keratinized Tissues.Antibiotics (Basel, Switzerland) · 2026
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

Abstract

Indexed as